SubcisionNCT07028567
Subcision Followed by Diluted Calcium Hydroxylapatite Injection Versus Subcision Followed by Painting CROSS TCA Technique for the Treatment of Atrophic Acne Scars
A study testing Calcium hydroxylapatite filler and Painting chemical reconstruction of skin scars trichloroacetic acid technique in people with Subcision and Calcium Hydroxylapatite, run by Tanta University at 1 site in Egypt.
Trial summary
This study aimed to compare the safety and efficacy of subcision followed by diluted calcium hydroxyapatite injection versus subcision followed by the painting original chemical reconstruction of skin scars (CROSS) technique using trichloroacetic acid (TCA) for the treatment of atrophic acne scars. Read more about this study
- Who is it for?
- Ages 20 to 50 years
- Conditions the study is for
- Subcision, Calcium Hydroxylapatite, Trichloroacetic Acid
- What is being tested?
- Calcium hydroxylapatite filler and Painting chemical reconstruction of skin scars trichloroacetic acid technique
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 13 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Jan 2023to 22 Jun 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 50 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Age from 20 to 50 years.
- Both sexes.
- Patients with atrophic acne scars.
Who cannot join
- Patients with Fitzpatrick skin phototypes V and VI.
- Receiving systemic isotretinoin medication at the time of the study.
- Active bacterial, viral or fungal infections in the treatment area.
- Hypertrophic scarring or keloidal tendency.
- Photosensitivity or photodermatitis.
- Unrealistic expectation, bleeding, coagulation disorders, and any other related skin disease.
Show all 9Show fewer
- Pregnant or lactating females.
- Chronic debilitating diseases such as diabetes mellitus, cardiovascular diseases, renal failure, hepatic diseases, chronic respiratory diseases or any endocrine diseases.
- History of immunosuppressive drug intake or chemotherapy within 6 months before treatment.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Comparative Study of Subcision Followed by Diluted Calcium Hydroxylapatite Injection Versus Subcision Followed by Painting CROSS TCA Technique for the Treatment of Atrophic Acne Scars
This study aimed to compare the safety and efficacy of subcision followed by diluted calcium hydroxyapatite injection versus subcision followed by the painting original chemical reconstruction of skin scars (CROSS) technique using trichloroacetic acid (TCA) for the treatment of atrophic acne scars.
Read the detailed description
Atrophic scars present as depressions secondary to fibrous contractions. Subcision is a technique in which a needle is inserted under the acne scar to sever the fibrous tissue (tethers) that bind down the scar. This releases the fibrous tissue.
The original chemical reconstruction of skin scars (CROSS) technique using trichloroacetic acid (TCA) entails focal application of highly concentrated TCA (70% to 100%) with firm pressure applied to the entire atrophic area using a sharpened wooden applicator until frosting occurs.
Fillers containing hyaluronic acid, calcium hydroxyapatite, and poly-L-lactic acid are increasingly used to correct atrophic acne scarring as they augment soft tissue in variable degree and are most effective in soft rolling or boxcar scars.
- Being tested
- Calcium hydroxylapatite filler, Painting chemical reconstruction of skin scars trichloroacetic acid technique
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Calcium hydroxylapatite fillerDrug
Patients received calcium hydroxylapatite filler (CaHA) (Radiesse®).
Painting chemical reconstruction of skin scars trichloroacetic acid techniqueDrug
Patients received painting chemical reconstruction of skin scars (CROSS) trichloroacetic acid (TCA) technique.
| Study group | Role | What they receive |
|---|---|---|
| Study group | Experimental | Patients with atrophic acne scars. Receives: Drug: Calcium hydroxylapatite filler; Drug: Painting chemical reconstruction of skin scars trichloroacetic acid technique |
What is being measured
The primary outcome is the main question the study is designed to answer.
Patient satisfaction
Patient satisfaction was assessed at the final follow-up visit using a 5-point Likert-type scale, comparing outcomes to the pre-treatment condition. The scale ranged from 1 (highly dissatisfied), 2 (slightly dissatisfied), 3 (neither satisfied nor dissatisfied), 4 (satisfied), to 5 (highly satisfied).
Measured: One week
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Jun 2025
- Study start1 Jan 2023
- Primary completion22 Jun 2023
- Study completion22 Jun 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for SubcisionStudies of the same condition, open and under way.
- More trials run by Tanta UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 13 participants (actual)
Sponsor and investigators
- Lead sponsor
- Tanta University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Riham Mohamed ElSayed ElSetiha, Tanta University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07028567
- Sponsor's protocol ID
- 36195/12/22
- Status last verified
- Jun 2025
- First submitted
- 11 Jun 2025
- Last updated
- 19 Jun 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Study at a glance
From the registry record, last updated by the sponsor on 19 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparative Study of Subcision Followed by Diluted Calcium Hydroxylapatite Injection Versus Subcision Followed by Painting CROSS TCA Technique for the Treatment of Atrophic Acne Scars
- ClinicalTrials.gov ID
- NCT07028567
- Acronym / sponsor ID
- 36195/12/22
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 13 participants (actual)
- Lead sponsor
- Tanta UniversityUniversity, hospital or other
- Study start
- 1 Jan 2023 (actual)
- Primary completion
- 22 Jun 2023 (actual)
- Study completion
- 22 Jun 2023 (actual)
- First posted
- 19 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aimed to compare the safety and efficacy of subcision followed by diluted calcium hydroxyapatite injection versus subcision followed by the painting original chemical reconstruction of skin scars (CROSS) technique using trichloroacetic acid (TCA) for the treatment of atrophic acne scars.
Detailed description
Atrophic scars present as depressions secondary to fibrous contractions. Subcision is a technique in which a needle is inserted under the acne scar to sever the fibrous tissue (tethers) that bind down the scar. This releases the fibrous tissue.
The original chemical reconstruction of skin scars (CROSS) technique using trichloroacetic acid (TCA) entails focal application of highly concentrated TCA (70% to 100%) with firm pressure applied to the entire atrophic area using a sharpened wooden applicator until frosting occurs.
Fillers containing hyaluronic acid, calcium hydroxyapatite, and poly-L-lactic acid are increasingly used to correct atrophic acne scarring as they augment soft tissue in variable degree and are most effective in soft rolling or boxcar scars.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Study group | Experimental | Drug: Calcium hydroxylapatite filler, Drug: Painting chemical reconstruction of skin scars trichloroacetic acid techniquePatients with atrophic acne scars. |
Who may qualify
- Ages
- 20 to 50 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Age from 20 to 50 years.
- Both sexes.
- Patients with atrophic acne scars.
Key exclusion criteria (9 listed)
- Patients with Fitzpatrick skin phototypes V and VI.
- Receiving systemic isotretinoin medication at the time of the study.
- Active bacterial, viral or fungal infections in the treatment area.
- Hypertrophic scarring or keloidal tendency.
- Photosensitivity or photodermatitis.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Calcium hydroxylapatite fillerPatients received calcium hydroxylapatite filler (CaHA) (Radiesse®). | Drug | Study group |
| Painting chemical reconstruction of skin scars trichloroacetic acid techniquePatients received painting chemical reconstruction of skin scars (CROSS) trichloroacetic acid (TCA) technique. | Drug | Study group |
Primary outcome
Patient satisfaction
Time frame: One week
Patient satisfaction was assessed at the final follow-up visit using a 5-point Likert-type scale, comparing outcomes to the pre-treatment condition. The scale ranged from 1 (highly dissatisfied), 2 (slightly dissatisfied), 3 (neither satisfied nor dissatisfied), 4 (satisfied), to 5 (highly satisfied).
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Jun 2025.
- Individual participant dataSharing planned: Yes. The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Related trials for Subcision
Active, not recruiting
Cyrolipolysis vs Cyrolipolysis and Subcision for Cellulite
Cellulite
Recruiting
Subcision With Injection of Poly Deoxyribonucleotide Versus Subcision With Injection of Non-cross Linked Hyaluronic Acid in Rolling Acne Scars Treatment.
Atrophic Acne Scars
Not yet recruiting
Subcision With CO₂ Laser or PRP vs Subcision Alone in Atrophic Acne Scars
Atrophic Acne Scar
Not yet recruiting
The Efficacy of Combination Therapy in Atrophic Scars
Atrophic Scar
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Calcium hydroxylapatite filler and Painting chemical reconstruction of skin scars trichloroacetic acid technique in people with Subcision and Calcium Hydroxylapatite, run by Tanta University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Patient satisfaction (time frame: One week). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Jun 2025.